Please use this identifier to cite or link to this item:
Title: Do product innovation and news about the R&D process produce large price changes and overreaction?: the case of pharmaceutical stock prices
Authors: Pérez Rodríguez, Jorge Vicente 
González Lopez-Valcarcel, Beatriz 
UNESCO Clasification: 531207 Sanidad
Keywords: Medicamentos
Issue Date: 2012
Publisher: 0003-6846
Journal: Applied economics (Print) 
Abstract: Do extreme price changes of pharmaceutical stocks reflect unexpected scientific information produced during the drug R&D process, especially the approval of new drugs, but also pre- and clinical trial results, recalls and withdrawals? Do stock prices initially overreact to such information? We modelled market-adjusted daily changes in stock prices of the 17 biggest pharmaceutical firms worldwide for the period from 1989 to 2008 to detect large price changes (outliers), using an Autoregressive Moving Average-Generalized Autoregressive Conditional Heteroscedasticity (ARMA-GARCH) dynamic econometric model. Then, we matched those outliers with news produced during the drug R&D process, and tested the hypothesis of no overreaction by examining cumulative abnormal returns. Our results show that there were 261 abnormal market-adjusted daily returns. In 60% of the cases, we were able to assign a plausible cause; i.e. Food and Drug Administration (FDA) approvals in 6% of these cases, news of a scientific nature in another 25%. Only 10 of 1721 FDA approvals of new drugs during the study period were related to abnormally large returns. The impact of negative news items on stock prices is larger than of positive news items. The overreaction hypothesis is rejected; there is no price backlash, therefore, the efficient market hypothesis is not violated.
ISSN: 0003-6846
DOI: 10.1080/00036846.2011.562172
Source: Applied Economics[ISSN 0003-6846],v. 44, p. 2217-2229
Appears in Collections:Artículos
Show full item record


checked on Aug 14, 2022


checked on Aug 14, 2022

Page view(s)

checked on Jul 24, 2022

Google ScholarTM




Export metadata

Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.